SUNHO BIOLOGICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.06 HKD | -5.02% |
|
-12.17% | 0.00% |
| May. 24 | Hong Kong Shares End Week in Red; Sunho Biologics Gains in Debut | MT |
| May. 24 | Sunho Biologics Shares Rise 7% in Hong Kong Debut | MT |
| Sales 2022 | 1.85M 255K 1.99M | Sales 2023 | 17.53M 2.41M 18.85M | Capitalization | 894M 123M 962M |
|---|---|---|---|---|---|
| Net income 2022 | -52M -7.16M -55.9M | Net income 2023 | -133M -18.32M -143M | EV / Sales 2022 * | - |
| Net cash position 2022 * | - 0 0 | Net cash position 2023 * | - 0 0 | EV / Sales 2023 * | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 * |
-
| Employees | - |
| Yield 2022 * |
-
| Yield 2023 * |
-
| Free-Float | 30.47% |
More Fundamentals
* Assessed data
| 1 day | -5.02% | ||
| 1 week | -12.17% | ||
| Current month | -14.65% |
1 week
5.86
6.91
1 month
5.8615.42
Current year
5.8615.42
1 year
5.8615.42
3 years
5.8615.42
5 years
5.8615.42
10 years
5.8615.42
Sunho Biologics Inc is a company mainly engaged in the research, development and production of biotechnology. The Company is primarily engaged in the discovery, development and commercialization of biologics that modulate the immune microenvironment by directly modulating the innate and adaptive immune systems. The Company has three core products, namely IAH0968, IAP0971 and IAE0972. IAH0968 is an antibody-dependent cell-mediated cytotoxicity-enhancing monoclonal antibody. IAP0971 and IAE0972 are both antibody cytokines.
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 123M | |
| +34.14% | 51.51B | |
| -6.54% | 39.03B | |
| +34.92% | 38.91B | |
| -12.11% | 26.68B | |
| +12.62% | 26.13B | |
| -13.43% | 19.91B | |
| +43.73% | 13.71B | |
| +31.81% | 12.38B | |
| -4.54% | 11.74B |
- Stock Market
- Equities
- 2898 Stock
